Stanojević-Bakić N, Vucković-Dekić L, Susnjar S, Spuzić I
Institute of Oncology and Radiology, Beograd, Yugoslavia.
Neoplasma. 1992;39(2):129-32.
There is some evidence that prostaglandin (PGE)-secreting cells may have a role in immunosuppression in cancer patients. In this work we investigated the effects of indomethacin--a PGE synthesis inhibitor, on PHA-induced lymphoproliferative response in vitro. Twenty patients with lung cancer before therapy were included in this study. When compared to controls, the patients had significant decrease of T cell number and proliferative response to PHA (p less than 0.001) and increased number of mononuclear phagocyting cells (p less than 0.001). The degree of depression of lymphocyte response did not correlate with the number of mononuclear phagocytes. The presence of indomethacin in the culture induced significant (p less than 0.01) improvement of the reactivity in high percentage (75%) of patients with diminished lymphoproliferative response to PHA. In the patients with normal lymphocyte response, indomethacin did not change reactivity to PHA. These results indicate that PGE-secreting cells may contribute to the immune depression in lung cancer patients, and that indomethacin may have therapeutical potential in some patients.
有证据表明，分泌前列腺素（PGE）的细胞可能在癌症患者的免疫抑制中起作用。在这项研究中，我们研究了吲哚美辛（一种PGE合成抑制剂）对体外PHA诱导的淋巴细胞增殖反应的影响。本研究纳入了20例治疗前的肺癌患者。与对照组相比，患者的T细胞数量和对PHA的增殖反应显著降低（p<0.001），单核吞噬细胞数量增加（p<0.001）。淋巴细胞反应的抑制程度与单核吞噬细胞的数量无关。培养物中吲哚美辛的存在使对PHA淋巴细胞增殖反应减弱的高比例（75%）患者的反应性显著改善（p<0.01）。在淋巴细胞反应正常的患者中，吲哚美辛不会改变对PHA的反应性。这些结果表明，分泌PGE的细胞可能导致肺癌患者的免疫抑制，并且吲哚美辛可能对某些患者具有治疗潜力。
